Sanofi's $1.7B rare dis­ease gam­bit; CAR-T boxed warn­ing saga; New biotechs on Nas­daq; A sell­er's mar­ket for M&A?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Will the first two biotech IPOs of the year — both up­sized — pave the way for a rosy pub­lic mar­ket? How about the out­look for buy­outs? Don’t miss our analy­sis on these top­ics, and stay tuned as we find out Big Phar­ma’s view at earn­ings next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER